AIXC beat EPS expectations by 91.47%
Nov 22, 2025, 11:34 PM
0.00%
What does AIXC do
Qualigen Therapeutics, a biotechnology company based in Los Angeles, focuses on cancer and infectious disease treatments, with its lead program QN-302 in Phase 1a trials. The company has one early-clinical-stage and one preclinical program targeting RAS oncogene interactions.
AIxCrypto Holdings (AIXC) reported a positive EPS surprise in its most recent quarterly earnings. For the most recent quarter, AIxCrypto Holdings's actual EPS was -$4.00, beating the estimate of -$46.92 per share, resulting in a 91.47% surprise.
📡️ Health Care
Earnings Surprise
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.